IDBiologics

On October 17, 2022, Vanderbilt University launched “Discovery Vanderbilt” to embolden faculty, students and staff to pursue innovative ideas through disciplined, rigorous inquiry. Led by Provost Cybele Raver, the university committed $80 million in the effort—and invested $50 million in the first year alone. Read More

Seed and Series A funding to three startups—HeroWear, IDBiologics and Virtuoso—rooted in research conducted at Vanderbilt University and Vanderbilt University Medical Center underscore a university-wide commitment to enhanced support for Vanderbilt’s most innovative faculty, students and alumni. Read More

The Center for Technology Transfer and Commercialization continued to play a pivotal role in translating the research findings of Vanderbilt faculty into products and companies in 2020 that have the potential to transform many aspects of life, from disease prevention to quality of life-enhancing products. Read More

To keep pace with Vanderbilt researchers developing COVID-19 solutions, the Center for Technology Transfer & Commercialization has facilitated three license agreements, 11 patent applications and 43 material transfer agreements in record time. Read More

Researchers at Vanderbilt University Medical Center are partnering with the Dutch biopharmaceutical firm Batavia Biosciences and Nashville-based IDBiologics to bring to the clinic a highly potent Zika virus neutralizing antibody they isolated three years ago. Read More